메뉴 건너뛰기




Volumn 19, Issue 6, 2013, Pages 1306-1321

Do inflammatory bowel disease therapies cause cancer?

Author keywords

Anti tumor necrosis factor; Inflammatory bowel disease; Malignancy; Methotrexate; Thiopurine

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 84879195556     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182807618     Document Type: Review
Times cited : (60)

References (76)
  • 1
    • 80053565309 scopus 로고    scopus 로고
    • Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis
    • Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1895-1904
    • Mariette, X.1    Matucci-Cerinic, M.2    Pavelka, K.3
  • 2
    • 67549117204 scopus 로고    scopus 로고
    • The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
    • Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-1145.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1136-1145
    • Leombruno, J.P.1    Einarson, T.R.2    Keystone, E.C.3
  • 3
    • 66149084485 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register
    • Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648-653.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 648-653
    • Askling, J.1    Baecklund, E.2    Granath, F.3
  • 4
    • 40449106365 scopus 로고    scopus 로고
    • Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis
    • Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168: 378-381.
    • (2008) Arch Intern Med. , vol.168 , pp. 378-381
    • Bernatsky, S.1    Clarke, A.E.2    Suissa, S.3
  • 5
    • 34248547187 scopus 로고    scopus 로고
    • The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
    • Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433-1439.
    • (2007) Arthritis Rheum. , vol.56 , pp. 1433-1439
    • Wolfe, F.1    Michaud, K.2
  • 6
    • 34848893989 scopus 로고    scopus 로고
    • Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
    • Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
    • (2007) Arthritis Rheum. , vol.56 , pp. 2886-2895
    • Wolfe, F.1    Michaud, K.2
  • 7
    • 33644892763 scopus 로고    scopus 로고
    • Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
    • Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
    • (2006) Arthritis Rheum. , vol.54 , pp. 692-701
    • Baecklund, E.1    Iliadou, A.2    Askling, J.3
  • 8
    • 33749346419 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis
    • Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757-2764.
    • (2006) Arthritis Rheum. , vol.54 , pp. 2757-2764
    • Setoguchi, S.1    Solomon, D.H.2    Weinblatt, M.E.3
  • 9
    • 27744520447 scopus 로고    scopus 로고
    • Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    • Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414-1420.
    • (2005) Ann Rheum Dis. , vol.64 , pp. 1414-1420
    • Askling, J.1    Fored, C.M.2    Baecklund, E.3
  • 10
    • 17644374819 scopus 로고    scopus 로고
    • Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    • Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703.
    • (2005) Ann Rheum Dis. , vol.64 , pp. 699-703
    • Geborek, P.1    Bladstrom, A.2    Turesson, C.3
  • 11
    • 0036624739 scopus 로고    scopus 로고
    • Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France
    • Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909-3915.
    • (2002) Blood. , vol.99 , pp. 3909-3915
    • Mariette, X.1    Cazals-Hatem, D.2    Warszawki, J.3
  • 12
    • 37749038302 scopus 로고    scopus 로고
    • The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study
    • Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67:74-79.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 74-79
    • Bernatsky, S.1    Joseph, L.2    Boivin, J.F.3
  • 13
    • 45349083403 scopus 로고    scopus 로고
    • Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate
    • Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794-799.
    • (2008) Arthritis Rheum. , vol.59 , pp. 794-799
    • Buchbinder, R.1    Barber, M.2    Heuzenroeder, L.3
  • 14
    • 33748757890 scopus 로고    scopus 로고
    • Lymphoma risk in psoriasis: Results of the PUVA follow-up study
    • Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142:1132-1135.
    • (2006) Arch Dermatol. , vol.142 , pp. 1132-1135
    • Stern, R.S.1
  • 15
    • 78751685797 scopus 로고    scopus 로고
    • Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
    • Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119-130.
    • (2011) Pharmacoepidemiol Drug Saf. , vol.20 , pp. 119-130
    • Askling, J.1    Fahrbach, K.2    Nordstrom, B.3
  • 16
    • 67549122368 scopus 로고    scopus 로고
    • Etanercept therapy in rheumatoid arthritis and the risk of malignancies: A systematic review and individual patient data meta-analysis of randomised controlled trials
    • Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68:1177-1183.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1177-1183
    • Bongartz, T.1    Warren, F.C.2    Mines, D.3
  • 17
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
    • (2006) JAMA , vol.295 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3
  • 18
    • 84866175338 scopus 로고    scopus 로고
    • Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
    • Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012; 64:1263-1271.
    • (2012) Arthritis Rheum. , vol.64 , pp. 1263-1271
    • Beukelman, T.1    Haynes, K.2    Curtis, J.R.3
  • 19
    • 70350548170 scopus 로고    scopus 로고
    • Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?
    • Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60:3180-3189.
    • (2009) Arthritis Rheum. , vol.60 , pp. 3180-3189
    • Askling, J.1    Van Vollenhoven, R.F.2    Granath, F.3
  • 20
    • 27744527575 scopus 로고    scopus 로고
    • Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
    • Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421-1426.
    • (2005) Ann Rheum Dis. , vol.64 , pp. 1421-1426
    • Askling, J.1    Fored, C.M.2    Brandt, L.3
  • 21
    • 27744499707 scopus 로고    scopus 로고
    • Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors
    • Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135.
    • (2005) J Rheumatol. , vol.32 , pp. 2130-2135
    • Chakravarty, E.F.1    Michaud, K.2    Wolfe, F.3
  • 22
    • 0034046385 scopus 로고    scopus 로고
    • Psoriasis, its treatment, and cancer in a cohort of Finnish patients
    • Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114:587-590.
    • (2000) J Invest Dermatol. , vol.114 , pp. 587-590
    • Hannuksela-Svahn, A.1    Pukkala, E.2    Laara, E.3
  • 23
    • 0029934518 scopus 로고    scopus 로고
    • Risk of cancer from azathio-prine therapy in multiple sclerosis: A case-control study
    • Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathio-prine therapy in multiple sclerosis: a case-control study. Neurology. 1996; 46:1607-1612.
    • (1996) Neurology , vol.46 , pp. 1607-1612
    • Confavreux, C.1    Saddier, P.2    Grimaud, J.3
  • 24
    • 0029759669 scopus 로고    scopus 로고
    • Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
    • Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738-745.
    • (1996) Br J Rheumatol. , vol.35 , pp. 738-745
    • Jones, M.1    Symmons, D.2    Finn, J.3
  • 25
    • 0028242317 scopus 로고
    • The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study
    • Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994;73:2759-2764.
    • (1994) Cancer , vol.73 , pp. 2759-2764
    • Stern, R.S.1    Laird, N.2
  • 26
    • 67949112671 scopus 로고    scopus 로고
    • Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
    • Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
    • (2009) Clin Gastroenterol Hepatol. , vol.7 , pp. 874-881
    • Siegel, C.A.1    Marden, S.M.2    Persing, S.M.3
  • 27
    • 33846448180 scopus 로고    scopus 로고
    • Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease
    • Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21-28.
    • (2007) Ann Pharmacother. , vol.41 , pp. 21-28
    • Masunaga, Y.1    Ohno, K.2    Ogawa, R.3
  • 28
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
    • (2005) Gut. , vol.54 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3
  • 29
    • 84863432006 scopus 로고    scopus 로고
    • Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease
    • Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063-2071.
    • (2012) Inflamm Bowel Dis. , vol.18 , pp. 2063-2071
    • Sokol, H.1    Beaugerie, L.2    Maynadie, M.3
  • 30
    • 82955195113 scopus 로고    scopus 로고
    • Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease
    • Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-2153.
    • (2011) Am J Gastroenterol. , vol.106 , pp. 2146-2153
    • Herrinton, L.J.1    Liu, L.2    Weng, X.3
  • 31
    • 77954426838 scopus 로고    scopus 로고
    • Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study
    • Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010;105:1604-1609.
    • (2010) Am J Gastroenterol. , vol.105 , pp. 1604-1609
    • Armstrong, R.G.1    West, J.2    Card, T.R.3
  • 32
    • 70449100743 scopus 로고    scopus 로고
    • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study
    • Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374: 1617-1625.
    • (2009) Lancet. , vol.374 , pp. 1617-1625
    • Beaugerie, L.1    Brousse, N.2    Bouvier, A.M.3
  • 33
    • 55149124689 scopus 로고    scopus 로고
    • Infliximab for inflammatory bowel disease in Denmark 1999-2005: Clinical outcome and follow-up evaluation of malignancy and mortality
    • quiz 1176
    • Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6: 1212-1217; quiz 1176.
    • (2008) Clin Gastroenterol Hepatol. , vol.6 , pp. 1212-1217
    • Caspersen, S.1    Elkjaer, M.2    Riis, L.3
  • 34
    • 0034764110 scopus 로고    scopus 로고
    • Inflammatory bowel disease is not associated with an increased risk of lymphoma
    • Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-1087.
    • (2001) Gastroenterology , vol.121 , pp. 1080-1087
    • Lewis, J.D.1    Bilker, W.B.2    Brensinger, C.3
  • 35
    • 0036024192 scopus 로고    scopus 로고
    • Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
    • Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225-1232.
    • (2002) Aliment Pharmacol Ther. , vol.16 , pp. 1225-1232
    • Fraser, A.G.1    Orchard, T.R.2    Robinson, E.M.3
  • 36
    • 0033795223 scopus 로고    scopus 로고
    • Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
    • Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
    • (2000) Gut. , vol.47 , pp. 514-519
    • Farrell, R.J.1    Ang, Y.2    Kileen, P.3
  • 37
    • 0028363515 scopus 로고
    • Long-term Neoplasia risk after azathioprine treatment in inflammatory bowel disease
    • Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343: 1249-1252.
    • (1994) Lancet. , vol.343 , pp. 1249-1252
    • Connell, W.R.1    Kamm, M.A.2    Dickson, M.3
  • 38
    • 84864225717 scopus 로고    scopus 로고
    • Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease
    • Long MD, Martin C, Pipkin CA, et al. Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.
    • (2012) Gastroenterology , vol.143 , pp. 390-399
    • Long, M.D.1    Martin, C.2    Pipkin, C.A.3
  • 39
    • 44649187924 scopus 로고    scopus 로고
    • Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
    • Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
    • (2008) Clin Gastroenterol Hepatol. , vol.6 , pp. 644-653
    • Peyrin-Biroulet, L.1    Deltenre, P.2    De Suray, N.3
  • 40
    • 80054865266 scopus 로고    scopus 로고
    • Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease
    • Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620.
    • (2011) Gastroenterology , vol.141 , pp. 1612-1620
    • Singh, H.1    Nugent, Z.2    Demers, A.A.3
  • 41
    • 79955025395 scopus 로고    scopus 로고
    • Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased
    • e441; author reply 450-441
    • van Schaik FD, van Oijen MG, Smeets HM, et al. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol. 2011;9:449-450 e441; author reply 450-441.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 449-450
    • Van Schaik, F.D.1    Van Oijen, M.G.2    Smeets, H.M.3
  • 42
    • 77349117814 scopus 로고    scopus 로고
    • Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
    • Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
    • (2010) Clin Gastroenterol Hepatol. , vol.8 , pp. 268-274
    • Long, M.D.1    Herfarth, H.H.2    Pipkin, C.A.3
  • 43
    • 58949091573 scopus 로고    scopus 로고
    • Risk of cervical abnormalities in women with inflammatory bowel disease: A population-based nested case-control study
    • Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136:451-458.
    • (2009) Gastroenterology , vol.136 , pp. 451-458
    • Singh, H.1    Demers, A.A.2    Nugent, Z.3
  • 44
    • 63849251824 scopus 로고    scopus 로고
    • Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
    • Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
    • (2009) Gut. , vol.58 , pp. 501-508
    • Fidder, H.1    Schnitzler, F.2    Ferrante, M.3
  • 45
    • 40949087267 scopus 로고    scopus 로고
    • Higher incidence of abnormal Pap smears in women with inflammatory bowel disease
    • Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103: 631-636.
    • (2008) Am J Gastroenterol. , vol.103 , pp. 631-636
    • Kane, S.1    Khatibi, B.2    Reddy, D.3
  • 46
    • 33750631422 scopus 로고    scopus 로고
    • Abnormalities of uterine cervix in women with inflammatory bowel disease
    • Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006; 12:6167-6171.
    • (2006) World J Gastroenterol. , vol.12 , pp. 6167-6171
    • Bhatia, J.1    Bratcher, J.2    Korelitz, B.3
  • 47
    • 79951650570 scopus 로고    scopus 로고
    • Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study
    • Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766.
    • (2011) Inflamm Bowel Dis. , vol.17 , pp. 758-766
    • Biancone, L.1    Petruzziello, C.2    Orlando, A.3
  • 48
    • 11144329670 scopus 로고    scopus 로고
    • The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease
    • Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21-26.
    • (2005) J Clin Gastroenterol. , vol.39 , pp. 21-26
    • Glazier, K.D.1    Palance, A.L.2    Griffel, L.H.3
  • 49
    • 0032754121 scopus 로고    scopus 로고
    • Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine
    • Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248-3253.
    • (1999) Am J Gastroenterol. , vol.94 , pp. 3248-3253
    • Korelitz, B.I.1    Mirsky, F.J.2    Fleisher, M.R.3
  • 50
    • 0027731258 scopus 로고
    • Incidence and treatment of Neoplasia after transplantation
    • Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transpl. 1993;12:S328-S336.
    • (1993) J Heart Lung Transpl. , vol.12
    • Penn, I.1
  • 51
    • 34249908092 scopus 로고    scopus 로고
    • Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review
    • Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198.
    • (2007) Drugs. , vol.67 , pp. 1167-1198
    • Gutierrez-Dalmau, A.1    Campistol, J.M.2
  • 52
    • 35748941259 scopus 로고    scopus 로고
    • Posttransplant lymphoproliferative disorder
    • Everly MJ, Bloom RD, Tsai DE, et al. Posttransplant lymphoproliferative disorder. Ann Pharmacother. 2007;41:1850-1858.
    • (2007) Ann Pharmacother. , vol.41 , pp. 1850-1858
    • Everly, M.J.1    Bloom, R.D.2    Tsai, D.E.3
  • 53
    • 0034680005 scopus 로고    scopus 로고
    • Epstein-Barr virus infection
    • Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.
    • (2000) N Engl J Med. , vol.343 , pp. 481-492
    • Cohen, J.I.1
  • 54
    • 33644924057 scopus 로고    scopus 로고
    • A population-based study of skin cancer incidence and prevalence in renal transplant recipients
    • Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154:498-504.
    • (2006) Br J Dermatol. , vol.154 , pp. 498-504
    • Moloney, F.J.1    Comber, H.2    O'Lorcain, P.3
  • 55
    • 45749122644 scopus 로고    scopus 로고
    • Azathioprine treatment photosensitizes human skin to ultraviolet A radiation
    • Perrett CM, Walker SL, O'Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol. 2008; 159:198-204.
    • (2008) Br J Dermatol. , vol.159 , pp. 198-204
    • Perrett, C.M.1    Walker, S.L.2    O'Donovan, P.3
  • 56
    • 40349096481 scopus 로고    scopus 로고
    • More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: The role of azathioprine
    • de Graaf YG, Rebel H, Elghalbzouri A, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol. 2008;17: 349-355.
    • (2008) Exp Dermatol. , vol.17 , pp. 349-355
    • De Graaf, Y.G.1    Rebel, H.2    Elghalbzouri, A.3
  • 57
    • 53849115754 scopus 로고    scopus 로고
    • PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients
    • Harwood CA, Attard NR, O'Donovan P, et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer. 2008;99:1276-1284.
    • (2008) Br J Cancer , vol.99 , pp. 1276-1284
    • Harwood, C.A.1    Attard, N.R.2    O'Donovan, P.3
  • 58
    • 3242756741 scopus 로고    scopus 로고
    • Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation
    • Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104:822-828.
    • (2004) Blood. , vol.104 , pp. 822-828
    • Offman, J.1    Opelz, G.2    Doehler, B.3
  • 59
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: From immunosurveillance to tumor escape
    • Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
    • (2002) Nat Immunol. , vol.3 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3
  • 60
    • 0024242251 scopus 로고
    • Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study
    • Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988;47:988-992.
    • (1988) Ann Rheum Dis. , vol.47 , pp. 988-992
    • Silman, A.J.1    Petrie, J.2    Hazleman, B.3
  • 61
    • 33645782015 scopus 로고    scopus 로고
    • TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility
    • van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397-408.
    • (2006) Oncologist. , vol.11 , pp. 397-408
    • Van Horssen, R.1    Ten Hagen, T.L.2    Eggermont, A.M.3
  • 62
    • 34250761386 scopus 로고    scopus 로고
    • Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    • Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726.
    • (2007) Arch Dermatol. , vol.143 , pp. 719-726
    • Tyring, S.1    Gordon, K.B.2    Poulin, Y.3
  • 63
    • 77953103015 scopus 로고    scopus 로고
    • Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register
    • Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010; 62:755-763.
    • (2010) Arthritis Care Res (Hoboken) , vol.62 , pp. 755-763
    • Dixon, W.G.1    Watson, K.D.2    Lunt, M.3
  • 64
    • 70350061599 scopus 로고    scopus 로고
    • Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: Enigma, wrapped in mystery, enclosed in conundrum
    • Ransohoff RM. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum. Ann Neurol. 2009;66:259-261.
    • (2009) Ann Neurol. , vol.66 , pp. 259-261
    • Ransohoff, R.M.1
  • 65
    • 34247884424 scopus 로고    scopus 로고
    • Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial
    • Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
    • (2007) Gastroenterology , vol.132 , pp. 1672-1683
    • Targan, S.R.1    Feagan, B.G.2    Fedorak, R.N.3
  • 66
    • 0035865012 scopus 로고    scopus 로고
    • Cancer risk in patients with inflammatory bowel disease: A population-based study
    • Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91: 854-862.
    • (2001) Cancer , vol.91 , pp. 854-862
    • Bernstein, C.N.1    Blanchard, J.F.2    Kliewer, E.3
  • 67
    • 77954426269 scopus 로고    scopus 로고
    • Risk of extra-intestinal cancer in inflammatory bowel disease: Meta-analysis of population-based cohort studies
    • Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480-1487.
    • (2010) Am J Gastroenterol. , vol.105 , pp. 1480-1487
    • Pedersen, N.1    Duricova, D.2    Elkjaer, M.3
  • 68
    • 17644386242 scopus 로고    scopus 로고
    • Risk of haematopoietic cancer in patients with inflammatory bowel disease
    • Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622.
    • (2005) Gut. , vol.54 , pp. 617-622
    • Askling, J.1    Brandt, L.2    Lapidus, A.3
  • 69
    • 0030041584 scopus 로고    scopus 로고
    • Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
    • Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
    • (1996) Lancet. , vol.347 , pp. 215-219
    • Bouhnik, Y.1    Lemann, M.2    Mary, J.Y.3
  • 70
    • 0029817846 scopus 로고    scopus 로고
    • The long-term outcome of ulcerative colitis treated with 6-mercaptopurine
    • George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;91: 1711-1714.
    • (1996) Am J Gastroenterol. , vol.91 , pp. 1711-1714
    • George, J.1    Present, D.H.2    Pou, R.3
  • 71
    • 0024457688 scopus 로고
    • 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
    • Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
    • (1989) Ann Intern Med. , vol.111 , pp. 641-649
    • Present, D.H.1    Meltzer, S.J.2    Krumholz, M.P.3
  • 72
    • 0036143781 scopus 로고    scopus 로고
    • Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine
    • Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72-77.
    • (2002) Gastroenterology , vol.122 , pp. 72-77
    • Dayharsh, G.A.1    Loftus Jr., E.V.2    Sandborn, W.J.3
  • 73
    • 80051480954 scopus 로고    scopus 로고
    • Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study
    • Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837-1845.
    • (2011) Inflamm Bowel Dis. , vol.17 , pp. 1837-1845
    • Vos, A.C.1    Bakkal, N.2    Minnee, R.C.3
  • 74
    • 78650239266 scopus 로고    scopus 로고
    • A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
    • e31
    • Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41 e31.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 36-41
    • Kotlyar, D.S.1    Osterman, M.T.2    Diamond, R.H.3
  • 75
    • 77957836758 scopus 로고    scopus 로고
    • Hepatosplenic T-cell lymphoma in inflammatory bowel disease: A possible thiopurine-induced chromosomal abnormality
    • Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010;105:2299-2301.
    • (2010) Am J Gastroenterol. , vol.105 , pp. 2299-2301
    • Kotlyar, D.S.1    Blonski, W.2    Diamond, R.H.3
  • 76
    • 80054862378 scopus 로고    scopus 로고
    • Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
    • e1621-1625
    • Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-1628 e1621-1625. Diseases
    • (2011) Gastroenterology , vol.141 , pp. 1621-1628
    • Peyrin-Biroulet, L.1    Khosrotehrani, K.2    Carrat, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.